Literature DB >> 33979676

miRNA dysregulation is an emerging modulator of genomic instability.

Ana P Ferragut Cardoso1, Mayukh Banerjee1, Alexandra N Nail1, Angeliki Lykoudi1, J Christopher States2.   

Abstract

Genomic instability consists of a range of genetic alterations within the genome that contributes to tumor heterogeneity and drug resistance. It is a well-established characteristic of most cancer cells. Genome instability induction results from defects in DNA damage surveillance mechanisms, mitotic checkpoints and DNA repair machinery. Accumulation of genetic alterations ultimately sets cells towards malignant transformation. Recent studies suggest that miRNAs are key players in mediating genome instability. miRNAs are a class of small RNAs expressed in most somatic tissues and are part of the epigenome. Importantly, in many cancers, miRNA expression is dysregulated. Consequently, this review examines the role of miRNA dysregulation as a causal step for induction of genome instability and subsequent carcinogenesis. We focus specifically on mechanistic studies assessing miRNA(s) and specific subtypes of genome instability or known modes of genome instability. In addition, we provide insight on the existing knowledge gaps within the field and possible ways to address them.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chromosomal instability; DNA repair; Genomic instability; miRNA

Mesh:

Substances:

Year:  2021        PMID: 33979676      PMCID: PMC8576067          DOI: 10.1016/j.semcancer.2021.05.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  170 in total

Review 1.  Polo-like kinases: a team in control of the division.

Authors:  Barbara C M van de Weerdt; René H Medema
Journal:  Cell Cycle       Date:  2006-04-17       Impact factor: 4.534

2.  Prolonged Particulate Hexavalent Chromium Exposure Suppresses Homologous Recombination Repair in Human Lung Cells.

Authors:  Cynthia L Browning; Qin Qin; Deborah F Kelly; Rohit Prakash; Fabio Vanoli; Maria Jasin; John Pierce Wise
Journal:  Toxicol Sci       Date:  2016-07-22       Impact factor: 4.849

Review 3.  The array CGH and its clinical applications.

Authors:  Marwan Shinawi; Sau Wai Cheung
Journal:  Drug Discov Today       Date:  2008-07-17       Impact factor: 7.851

Review 4.  How the fanconi anemia pathway guards the genome.

Authors:  George-Lucian Moldovan; Alan D D'Andrea
Journal:  Annu Rev Genet       Date:  2009       Impact factor: 16.830

5.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

6.  Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.

Authors:  W M Abdel-Rahman; K Katsura; W Rens; P A Gorman; D Sheer; D Bicknell; W F Bodmer; M J Arends; A H Wyllie; P A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

7.  MicroRNA: Biogenesis, Function and Role in Cancer.

Authors:  Leigh-Ann Macfarlane; Paul R Murphy
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

Review 8.  MicroRNAs in the DNA Damage/Repair Network and Cancer.

Authors:  Alessandra Tessitore; Germana Cicciarelli; Filippo Del Vecchio; Agata Gaggiano; Daniela Verzella; Mariafausta Fischietti; Davide Vecchiotti; Daria Capece; Francesca Zazzeroni; Edoardo Alesse
Journal:  Int J Genomics       Date:  2014-01-30       Impact factor: 2.326

9.  Hsa-miR-155-5p drives aneuploidy at early stages of cellular transformation.

Authors:  Sara Pagotto; Angelo Veronese; Alessandra Soranno; Paola Lanuti; Mirco Di Marco; Marco Vincenzo Russo; Alice Ramassone; Marco Marchisio; Pasquale Simeone; Paolo E Guanciali-Franchi; Giandomenico Palka; Renato Mariani Costantini; Carlo M Croce; Rosa Visone
Journal:  Oncotarget       Date:  2018-02-07

Review 10.  Reactive oxygen species (ROS) as pleiotropic physiological signalling agents.

Authors:  Helmut Sies; Dean P Jones
Journal:  Nat Rev Mol Cell Biol       Date:  2020-03-30       Impact factor: 113.915

View more
  3 in total

1.  MiR-1224 Acts as a Prognostic Biomarker and Inhibits the Progression of Gastric Cancer by Targeting SATB1.

Authors:  Guo-Dong Han; Yuan Sun; Hong-Xia Hui; Ming-Yue Tao; Yang-Qing Liu; Jing Zhu
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

2.  MiR-144-3p inhibits gastric cancer progression and stemness via directly targeting GLI2 involved in hedgehog pathway.

Authors:  Yixun Lu; Benlong Zhang; Baohua Wang; Di Wu; Chuang Wang; Yunhe Gao; Wenquan Liang; Hongqing Xi; Xinxin Wang; Lin Chen
Journal:  J Transl Med       Date:  2021-10-17       Impact factor: 5.531

3.  MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.

Authors:  Veronika Petkova; Dora Marinova; Silva Kyurkchiyan; Gergana Stancheva; Evgeni Mekov; Darina Kachakova-Yordanova; Yanina Slavova; Dimitar Kostadinov; Vanyo Mitev; Radka Kaneva
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.